Business
CORRECTION – Inspira Signs Term Sheet for Acquisition of Advanced Liquid Biopsy Cancer Diagnostics Technology and Investment of $15 Million into Inspira at $180 Million Valuation
All-share acquisition positions Inspira to expand into a multi-billion dollar diagnostics market with a development-ready innovative technology; transaction structured to include significant protections for existing shareholders of Inspira relating to its existing technologiesRA'ANANA, Israel, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) ("Inspira" or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today announced it has
About this update from Qtrex Quantum Ltd.
[{"type":"image","alt":"Inspira Technologies","displaySize":"","headline":null,"caption":"Inspira Technologies","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":71,"url":"https://media.zenfs.com/en/globenewswire.com/f3cd7fe01a01b6d2fcb4b07615d7a878"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/_Fe6OoV8FaU0yBPMg3F6WQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTk5O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/f3cd7fe01a01b6d2fcb4b07615d7a878","width":300,"height":71}},"lazy":false},{"type":"text","content":"All-share acquisition positions Inspira to expand into a multi-billion dollar diagnostics market with a development-ready innovative technology; transaction structured to include significant protections for existing shareholders of Inspira relating to its existing technologies","length":277,"tagName":"p"},{"type":"text","content":"RA'ANANA, Israel, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) ("Inspira" or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today announced it has entered into a non-binding term sheet (the “Term Sheet”), outlining the principal terms of a proposed two-part transaction that would include the acquisition of an advanced liquid biopsy diagnostics business, together with a concurrent $15 million strategic equity investment into the Company, subject to the execution of definitive agreements (the “Definitive Agreements”). The Company expects to finalize and execute the Definitive Agreements within approximately the next four weeks, following which the transaction shall be subject to shareholder approval and customary closing conditions.","length":841,"tagName":"p"},{"type":"text","content":"Dagi Ben-Noon, Chief Executive Officer of Inspira, commented “We are positioning the Company to expand into a high-growth diagnostics market through the planned acquisition of a development-ready liquid biopsy platform, supported by a clear regulatory pathway, alongside a significant strategic equity investment of $15 million into the Company that reflects a valuation framework driven by the technology’s potential combined with our execution capabilities. Equally important, the transaction has been structured to protect our existing shareholders, preserving their full economic upside to all future reali...